Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.69 AUD
Change Today -0.01 / -1.44%
Volume 999.4K
ACR On Other Exchanges
As of 2:10 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

acrux ltd (ACR) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/1/14 - A$2.10
52 Week Low
07/29/15 - A$0.69
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACRUX LTD (ACR)

Related News

No related news articles were found.

acrux ltd (ACR) Related Businessweek News

No Related Businessweek News Found

acrux ltd (ACR) Details

Acrux Limited is engaged in the development and commercialization of healthcare products in Australia, Switzerland, the United States, and internationally. Its marketed products comprise Axiron for the treatment of testosterone deficiency in men; Recuvyra for pain relief of dogs; and Evamist for menopausal symptoms. The company’s product under registration study includes Estradiol MDTS for menopausal symptoms. It is also developing products, which are in formulation stage for the treatment of non-melanoma skin cancer, anti-fungal, pain and inflammation, and other diseases, as well as developing product for the treatment of animal health. The company was founded in 1998 and is headquartered in West Melbourne, Australia.

Founded in 1998

acrux ltd (ACR) Top Compensated Officers

Commercial Director
Total Annual Compensation: A$122.8K
Compensation as of Fiscal Year 2014.

acrux ltd (ACR) Key Developments

Acrux Limited Announces Sales Results for the Fourth Quarter and Fiscal Year Ended June 30, 2015

Acrux Limited announced sales results for the fourth quarter and fiscal year ended June 30, 2015. For the fiscal year ended 30 June 2015, the company earned royalties from Axiron of $19.2 million, compared to $22.3 million in the previous year. The company reported net sales of $155.4 million against $181.1 million a year ago. The company confirmed that net sales of $32.4 million in its financial results for the quarter ended 30 June 2015 against $47.1 million a year ago.

Acrux Limited Announces Resignation of Ross Barrow, Non-Executive Director

Acrux announced the resignation of Ross Barrow, Non-Executive Director.

Acrux Limited Announces Consolidated Earnings Results for the Six Months Ended December 31, 2014

Acrux Limited announced consolidated earnings results for the six months ended December 31, 2014. For the period, the company reported revenue and other income of AUD 14,218,000 against AUD 43,657,000 a year ago. Profit before income tax was AUD 10,284,000 against AUD 38,363,000 a year ago. Net profit from continuing operations was AUD 7,018,000 against AUD 24,590,000 a year ago. Total comprehensive income for the half year was AUD 7,018,000 against AUD 24,590,000 a year ago. Basic and diluted earnings per share for profit attributable to the equity holders of the parent entity were AUD 0.04 against AUD 0.15 a year ago. Net cash provided by operating activities was AUD 3,230,000 against AUD 7,692,000 a year ago. Payment for property, plant and equipment were AUD 13,000 against AUD 24,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACR:AU A$0.69 AUD -0.01

ACR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Austin Engineering Ltd A$0.44 AUD -0.01
Bradken Ltd A$1.20 AUD +0.005
Emeco Holdings Ltd A$0.08 AUD +0.001
Endo International PLC $86.19 USD -1.44
Seven Group Holdings Ltd A$5.54 AUD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation ACR Industry Range
Price/Earnings 10.3x
Price/Sales 4.5x
Price/Book 3.1x
Price/Cash Flow 8.8x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACRUX LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at